nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab']
for h&amp;n oncs: biomakers for screening diagnosis &amp; surveillance, 1 pm s504 abstracts 2:45 pm s406 (all nasopharyngeal ca): rt vs crt , adding nimotuzumab reduced rt for ebv low stage 3 risk-tailored therapy #asco22
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement